((自动化翻译由路透提供，请见免责声明 )) (更新)
9月19日 - ** Elanco Animal Health 股价下跌6.1%，最后下跌5.4%，报13.86美元。
** 摩根士丹利将ELAN的评级从 "增持 "下调至 "等权重"；将目标价从17美元下调至15美元
** 摩根士丹利将 ELAN 的评级从 "增持 "下调至 "等权重"；将目标价从 17 美元下调至 15 美元。
** 认为新产品的增长和上升空间有限，特别是考虑到 Zenrelia 的挫折。
** ELAN 于 6 月表示， 预计 (link) 在其狗皮炎治疗药物 Zenrelia 的美国标签中加入与安全相关的 "盒装警告"。
** 公司预计第四季度上市
** 15位分析师中有9位给予该股 "买入 "或更高评级，6位给予 "持有 "评级；他们的预测中值为20美元--LSEG数据
** 包括盘中走势在内，该股今年累计下跌约 7
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.